MO - Altria Group, Inc.

NYSE - NYSE Delayed Price. Currency in USD
50.86
-0.35 (-0.68%)
At close: 4:04PM EDT
Stock chart is not supported by your current browser
Previous Close51.21
Open51.11
Bid50.71 x 800
Ask50.89 x 1400
Day's Range50.48 - 51.48
52 Week Range42.40 - 66.04
Volume5,669,297
Avg. Volume8,137,533
Market Cap95.155B
Beta (3Y Monthly)0.35
PE Ratio (TTM)15.50
EPS (TTM)3.28
Earnings DateJul 30, 2019
Forward Dividend & Yield3.20 (6.52%)
Ex-Dividend Date2019-06-13
1y Target Est58.73
Trade prices are not sourced from all markets
  • The 5 Most Profitable Pot Stocks on the Planet
    Motley Fool6 hours ago

    The 5 Most Profitable Pot Stocks on the Planet

    Most cannabis companies are losing money. These aren't.

  • Goldman Sachs: 5 ‘Superstar’ Stocks To Buy Now
    TipRanks15 hours ago

    Goldman Sachs: 5 ‘Superstar’ Stocks To Buy Now

    Goldman Sachs has a new strategy for investors to consider. The firm has now revealed that the most dominant companies in an industry tend to outperform companies with a smaller percentage of market sales. There’s even a name for these kind of companies ‘superstar firms.’ “The market positioning of superstar firms often allows for greater bargaining power over consumers and workers and higher profitability,” Goldman's senior US equity strategist David Kostin told investors. “Superstar firms have been one driver of the explosion in US corporate margins post-crisis.”According to Kostin, companies with the highest share of industry sales have returned 49% since 2015. In contrast, companies with the lowest share of industry sales returned just 16% over the same time-frame. Here we take a closer look at five of the most prominent stocks in Goldman Sachs' 'superstar' portfolio. Should you buy into these names now? Let’s see what the Street has to say now… 1\. Altria (MO) * 88% share of industry US salesDuring the last five years, tobacco giant MO has gained 23%. That’s despite a disastrous 2018 which saw prices pullback 30%. So far in 2019, shares are holding steady- and Wells Fargo’s Bonnie Herzog spies upside ahead. She has just reiterated her Buy rating with a price target of $65 (28% upside potential). She believes that Altria will be able to weather the shift from traditional cigarettes to vapor products. “Major tobacco manufacturers are well-positioned in the current regulatory/political environment driven by strong management teams and a deep reservoir of bench talent and funds to drive innovation” says the analyst. Interestingly, Herzog adds that industry consolidation “will increasingly favor scale in the global ‘arms’ race in reduced-risk products (RRPs) while addressing the youth crisis.” Altria, for example, recently invested $12.8 billion in leading e-cigarette maker Juul Labs as well as a further $1.8 billion in cannabis stock Cronos Group (CRON). Luckily for Altria, Juul recently revealed Q1 sales of $528 million, up 23% from the previous quarter’s revenue. Now there is talk that Juul could be on the way to opening its own chain of vaping shops, starting in Houston and Dallas, Texas. Meanwhile Altria will also exclusively distribute Philip Morris International's (PM) "heat-not-burn" tobacco device. Called IQOS the device heats tobacco to around 350°C vs temperatures in excess of 600°C for a cigarette. “Because the tobacco is heated and not burned, the levels of harmful chemicals are significantly reduced compared to cigarette smoke” claims the company.Overall, we can see that the stock has a cautiously optimistic Moderate Buy analyst consensus. This is based on all the ratings received by the company over the last three months. Meanwhile the average analyst price target of $60 indicates upside potential of 18% from current levels. View MO Price Target & Analyst Ratings Detail 2\. Alphabet (GOOGL) * 63% share of industry US salesLooking back, GOOGL has almost doubled in value over the last five years. But that doesn’t mean there isn’t further upside potential ahead. GOOGL still retains a bullish ‘Strong Buy’ Street consensus. What’s more, the $1,334 average analyst price target indicates upside potential of over 22%. That’s despite more anti-trust talk from regulators, with Makan Delrahim (Assistant AG, DOJ) suggesting that stricter regulation may be coming.“Investors may be getting relatively comfortable with the underlying regulatory risk given that so far, the financial performance at FB, GOOGL and AMZN continues to be in line or even better than what the Street has been expecting” notes top-rated SunTrust Robinson analyst Youssef Squali. Given the complexity and global considerations of regulating and/or breaking up big tech, Squali is confident that it is likely to take years for regulatory measures to be implemented, and even longer for them to start impacting the financials of these companies. What’s more there is a growing realization that even in case of a break-up of a behemoth like GOOGL, the value of the parts may be higher than the whole over time. For example, Needham analyst Laura Martin has just reiterated her GOOGL buy rating with a $1,350 price target. She has calculated that the company could be worth nearly 50% more than its current valuation in the case of a break-up. Martin values Google search at $600 per Alphabet share, YouTube at $200, and the Android App Store at $100. Plus there are extra contributions from Gmail, Maps, Waymo, DeepMind etc. “Elevated regulatory scrutiny adds costs and margin pressures for 2-4 years, but probably has little impact on revenue growth or consumer usage until outcomes are determined and then fought out in the courts,” she concluded.View GOOGL Price Target & Analyst Ratings Detail 3\. General Electric (GE) * 51% share of industry US sales With new CEO Larry Culp at the helm, General Electric has put on a remarkable year-to-date rally of over 40%. The company was primed for a rebound after plunging over 50% in 2018. And analysts are currently divided about the stock’s outlook going forward.The key question is whether Culp’s multiyear turnaround plan will succeed to boost the company while reducing its massive $110 billion debt pile (as of March 31, according to FactSet). Cowen & Co’s Gautam Khanna sums up the problem here: “The major debates on GE's stock, which won't be resolved for years, are whether cost cutting & portfolio actions will return Industrial to sustained high FCF [free cash flow] conversion, & if Capital will require more cash support.” As a result, the analyst reiterates his Hold rating on GE with an $8 price target. That suggests shares could fall 20% from current levels. However, there are some more positive voices in the crowd. Most noticeably, William Blair’s Nicholas Heymann has just reiterated his GE Buy rating. He believes GE can ‘materially outperform’ the market over the next 12 months.“We continue to believe GE’s underlying intrinsic value (with no value assigned to Power) is somewhere in the range of $14-$16 per share,” the analyst revealed, describing this as a “highly feasible base-case valuation for GE’s share price over the next 6-12 months.”“The unbridled fear that overshadowed a rational assessment of the company’s underlying fair value exiting 2018 is beginning to recede and be replaced with far less ambiguous and more tangible plans and actions that will support a likely materially higher value for GE’s stock over the next 12 months and beyond,” said Heymann. View GE Price Target & Analyst Ratings Detail 4\. Walt Disney (DIS) * 49% share of industry US salesThis is a critical year for Walt Disney. As well as two new Star Wars attractions, DIS is also launching its own direct-to-consumer (DTC) streaming service known as Disney+. Clearly investors are feeling optimistic- boosted by the success of Avengers: Endgame (the second highest-grossing film of all time), shares are up 29% year-to-date. This brings Walt Disney’s total five-year gain of over 70%. It’s not just investors that are bullish on DIS right now. In the last three months, 16 analysts have published DIS Buy ratings vs just 3 Hold ratings. That gives DIS its ‘Strong Buy’ Street consensus. Meanwhile the average analyst price target of $153 indicates upside potential of 8%. “I believe that Disney+ will be a significant revenue driving opportunity along with the ongoing success of Disney Studios and Theme Parks” commented five-star Tigress Financial analyst Ivan Feinseth. “I further believe both Star Wars and Marvel franchises including a number of series from both these franchises will be significant drivers for Disney+ subscriptions,” Feinseth wrote. ‘Star Wars Episode IX: The Rise of Skywalker’ is set for release this December, and could also generate a whopping $2 billion in box office revenue.At the same time Morgan Stanley’s Benjamin Swinburne has just raised Disney’s long-term DTC subscribers and earnings estimates. This leads him to a new $160 price target and $210 bull case. He is now forecasting over 130mm global OTT subscribers by 2024, and is confident that DIS shares can sustain a premium multiple as the service ramps up. The analyst’s willingness to underwrite these higher estimates stems from: 1) A faster-than-expected global launch for Disney+; 2) More IP aggregating more quickly than anticipated; and 3) A plan to leverage third-party distribution. View DIS Price Target & Analyst Ratings Detail 5\. General Motors (GM) * 48% share of industry US salesOnly three analysts have published recent ratings on GM. Two analysts are staying neutral on the stock, while one analyst- Morgan Stanley’s Adam Jonas\- has a bullish rating on GM. Encouragingly, out of the three analysts, Jonas is the analyst with the strongest stock picking track record. Following relatively ‘in-line’ Q1 earnings results, Jonas reiterated his buy rating and Street-high price target of $44. From current levels that translates into 23% upside potential. According to the analyst, Q1 earnings didn’t fundamentally change his take on the GM story- especially if you strip away the mark-to-market ‘noise’ from the Lyft (LYFT) and PSA revaluations. Nonetheless, Jonas revealed that he was "sympathetic to some investor profit taking" after prices climbed 5% in April.And the analyst also moved to temper expectations surrounding GM’s self-driving Cruise unit. "While we think GM Cruise has important technological value, we urge investors to lower expectations on revenue generation and profitability of the unit," Jonas advised. "Taking nothing away from GM cruise, it is our understanding that the technology required to remove human drivers at an acceptable level of consumer safety is likely many years away." He continued: "And the legal and regulatory construct to support, even proven technology, may present even greater hurdles largely outside of GM Cruise's control."At the time of writing, General Motors has enjoyed a modest year-to-date rise of 7%. Despite rallying in both 2016, and 2017, 2018 was a more difficult year for GM investors with the stock losing 19%. View GM Price Target & Analyst Ratings DetailDiscover stock ideas from the Street’s best performing analysts here

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Altria Group Inc.

    Altria Group Inc NYSE:MOView full report here! Summary * Perception of the company's creditworthiness is neutral * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for MO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MO. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MO had net inflows of $9.65 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Consumer Goods sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. Although MO credit default swap spreads are decreasing, they remain near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 3 Medical Marijuana Stocks to Buy
    InvestorPlace3 days ago

    3 Medical Marijuana Stocks to Buy

    [Editor's note: This story was previously published in March 2019. It has since been updated and republished.]Often, when analysts or bloggers talk up the potential of marijuana stocks, the focus is on the consumer side of the industry. But some of the best stocks in the pot sector may be medical marijuana stocks.Indeed, it's on the medical side where growth likely is to be largest in the near term. Canada did legalize recreational marijuana in October, but investors promptly sold the news in response. U.S. legalization is likely to be a long slog. Attitudes are mixed in Europe -- but even in legalized markets anywhere, black market (and untaxed) operators will be able to take share.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMeanwhile, approval of medical marijuana (in the U.S. and elsewhere) seems to be moving at a faster pace. In such a highly regulated market, black market and even smaller producers likely will be shut out. Quality and consistency will be key. Here, scale will matter. And those companies that win early have the best chance of becoming market leaders -- and providing big gains for investors. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 As always -- and particularly in this space -- investors need to mind the risks and size positions accordingly. But for investors who see medical marijuana stocks as the next big thing, these three are the best stocks to buy for investors enamored with weed.Source: Shutterstock Charlotte's Web (CWBHF)Charlotte's Web (OTCMKTS:CWBHF) has become one of the leading players in CBD oil (cannabidiol). And though Charlotte's Web products are made from hemp -- at least for now -- instead of marijuana, the stock still looks like one of the best plays in the sector.InvestorPlace's Matt McCall named CWBHF (the stock also trades on the Canadian Securities Exchange, ticker CWEB) as his pick for our list of the best stocks for 2019. And the case makes some sense. CBD oil sales are soaring, and Charlotte's Web is a market leader. As McCall pointed out, the federal farm bill in the U.S. provided a catalyst by legalizing hemp.With so many customers yet to try CBD oil -- and so many existing users attached -- market growth should be huge. And while CWBHF isn't cheap from a valuation standpoint, its position as a market leader should allow it to grow into its valuation.Source: Shutterstock Cronos (CRON)Of late, marijuana producer Cronos Group (NASDAQ:CRON) has made the headlines for its consumer business. Most recently, tobacco giant Altria (NYSE:MO) invested some $1.8 billion in the company. The combination of Altria's advertising and distribution reach and Cronos' production capabilities would seem to be the best fit for the consumer side of the business.But investors can't ignore that Cronos is a medical marijuana stock as well. In fact, it's that business that drives the majority of its revenue at the moment. And it also has given the company a beachhead in multiple markets around the world, from its home market of Canada to Germany, Israel and Poland. * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 I wrote after the Altria deal that investors should stay patient with CRON stock. And in this market, that might still be wise advice.Source: Shutterstock CannTrust (CTST)CannTrust (NYSE:CTST) has been one of the biggest victims of the post-legalization selloff. The stock lost more than half its value and touched a 52-week low in the process last year. And it's been in an almost continuous slump again since March.Unlike many peers, the company usually posts gross profits. And its established leadership in the Canadian medical marijuana industry should drive consistent growth and allow CannTrust to stay profitable. There is some retail exposure here as well, but unlike peers, CannTrust seems to have room to drive upside on the medical side alone.CannTrust also was able to get a listing on the New York Stock Exchange this year. Admittedly, uplisting hasn't helped pot stocks in and of itself (most notably Aurora Cannabis (NYSE:ACB) took a lot longer to take off than was expected), but it certainly didn't hurt.From a profitability standpoint, at least, CNNTF seems like one of the best stocks in the pot sector. And with valuation near the lows, at least some of the risks here likely are priced in.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Stocks to Buy That Wall Street Expects to Soar for the Rest of 2019 * 7 Value Stocks That Are Flying Under the Radar * 6 Mouth-Watering Fast Food Stocks for Growth Investors Compare Brokers The post 3 Medical Marijuana Stocks to Buy appeared first on InvestorPlace.

  • Cronos Stock Could Be Worth the Bumpy Ride
    InvestorPlace4 days ago

    Cronos Stock Could Be Worth the Bumpy Ride

    Shares of Cronos Group Inc. (NASDAQ:CRON), the Canadian medical marijuana producer, have been on a roller coaster ride this year. In the first quarter, Cronos stock more than doubled, but as the quarter drew to a close, investors departed the name, sending the shares tumbling over the course of April and May.Source: Shutterstock This month, Cronos stock seems to have found round-number support at $14 and is rallying hard off that level. While the stock was pinched on June 11, to the tune of a 2.42% loss, it is still up 28% over just the past week.One of the obvious catalysts this month for Cronos stock was an upgrade by Bank of America analyst Christopher Carey coupled with an epic, upward price target revision by that analyst. Earlier this month, Carey lifted his rating on Cronos stock to "buy" from "underperform," the equivalent of a "double upgrade" because there is usually a rating in between "buy" and "underperform." Additionally, the analyst boosted his price target on Cronos stock to $20 from $13, implying a decent amount of upside from Tuesday's close of just under $17.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cronos ControversyAs is the case with so many cannabis stocks, opinions differ on Cronos stock. While Cronos has its share of supporters, there are also skeptical voices. At least one analyst prefers Aphria (NYSE:APHA) to Cronos, though the former is about $1.3 billion smaller than the latter in terms of market value. * 7 Stocks to Buy for the Coming Recession Jefferies analyst Owen Bennett said Aphria's strengths in extraction, capacity and its international strategy are attractive qualities, while noting Cronos stock is richly valued relative to its cannabis equity peer group.Contributing to the debate on Cronos stock, Stifel analyst Andrew Carter recently initiated coverage of the name with a "tepid" hold rating. However, Carter notes a sector-wide pullback could enable financially sturdy marijuana companies, including Cronos, to possibly scoop up some rivals at discounted valuations.Cronos has $1.8 billion in cash, one of the more impressive cash hoards in the legalized marijuana industry and one that really stands out when considering the company's market capitalization is just over $3 billion. That $1.8 billion is the sum tobacco giant Altria Group (NYSE:MO) previously invested in Cronos, and Altria CEO Howard Willard has been open about his company making that investment in Cronos to help medicinal marijuana firm make the moves it needs to make to bolster market share. Bottom Line on Cronos Stock: Looking South of the BorderCronos is a Canadian company and while recreational marijuana is legal across that entire country, the real opportunity for the company may lie south of the border in the U.S., where the company is looking to enter the fast-growing cannabidiol (CBD) market.CBD is the most popular cannabis-based derivative.Currently, much of the enthusiasm for CBD revolves around hope and speculation. Supporters believe it can be elixir for various medical ailments and other uses, but there is not much in the way of empirical scientific evidence to support those claims. The good news for Cronos stock, assuming the company can effectively execute a foray into the U.S. market, is that the segment is expected to deliver exponential growth.A recent study by BDS Analytics and Arcview Market Research says the U.S. CBD market could swell to $20 billion by 2024."In fact, BDS Analytics is predicting an compound annual growth rate of 49 percent by 2024 across all distribution channels," reports Forbes. "Also, they expect that the CBD market, combined with THC products, will create a total market of $45 billion for cannabinoids by 2014." * 7 High-Quality Cheap Stocks to Buy With $10 Bolstering the long-term case for Cronos stock are the various distribution channels for CBD, many of which are mainstream. The ride will include some volatility -- that is just the name of the game with cannabis stocks -- but Cronos stock is a compelling long-term idea if management executes the CBD opportunity the right way.As of this writing, Todd Shriber did not own any of the aforementioned securities.Compare Brokers The post Cronos Stock Could Be Worth the Bumpy Ride appeared first on InvestorPlace.

  • Barrons.com4 days ago

    Altria Stock Can Rise With the Company’s ‘Tremendous Pricing Power’

    An unexpected price increase for nearly all of the tobacco maker’s brands, emphasizes Altria’s pricing power and will be followed by the rest of the industry, Wells Fargo says.

  • Reuters4 days ago

    FDA proposes shorter deadline for e-cigarette applications

    The U.S. Food and Drug Administration said it can advance the date for the submission of e-cigarette applications, responding to a ruling that the agency had exceeded its authority by allowing e-cigarettes to remain on the market until 2022 before companies applied for regulatory approval. The FDA in a court filing on Wednesday proposed adoption of a timeline of not less than 10 months to submit the applications after a final ruling, if the court decides not to remand the case back to the agency for further action. "Should the Court order premarket applications to be submitted by a date certain, it should set that deadline no sooner than 10 months from the date of its decision, along with a one-year period for FDA review," FDA said in the court filing.

  • Altria (MO) Dips More Than Broader Markets: What You Should Know
    Zacks5 days ago

    Altria (MO) Dips More Than Broader Markets: What You Should Know

    Altria (MO) closed at $51.61 in the latest trading session, marking a -1.04% move from the prior day.

  • Benzinga5 days ago

    Why Tobacco Stocks Are Trading Down Wednesday

    British American Tobacco said in a news release Wednesday that it expects global industry volume to be down by around 3.5 percent in 2019. Despite a guide for lower volume shipments, British American said it remains on track for constant currency revenue growth in the mid-to-upper half of its long-term guidance of 3-5 percent.

  • The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk

    The Zacks Analyst Blog Highlights: Intel, Altria, Stryker, Sherwin-Williams and Verisk

  • Top Stock Reports for Intel, Altria & Stryker
    Zacks6 days ago

    Top Stock Reports for Intel, Altria & Stryker

    Top Stock Reports for Intel, Altria & Stryker

  • Benzinga6 days ago

    FDA Issues Guidelines for E-Cig Makers Seeking Approval Of Vape Devices

    Under FDA regulation of e-cigarettes that began in 2016, e-cigarettes, known by the agency as electronic nicotine delivery systems, or ENDS, that were already on the market had to apply for FDA approval to remain available after August 2021.

  • Moody's6 days ago

    Altria Group Inc. -- Moody's announces completion of a periodic review of ratings of Altria Group Inc.

    Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Altria Group Inc. New York, June 11, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Altria Group Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Why Much-Maligned Cronos Group Could Be a Sleeping Giant
    Motley Fool6 days ago

    Why Much-Maligned Cronos Group Could Be a Sleeping Giant

    While many are hating on Cronos Group, one analyst thinks the company is poised to be a big winner in the U.S.

  • The Most Hated Pot Stock Received a Rare Upgrade but Is Still Grossly Overvalued
    Motley Fool7 days ago

    The Most Hated Pot Stock Received a Rare Upgrade but Is Still Grossly Overvalued

    Bank of America sees 39% upside in this marijuana stock, but a lot would need to go right for that to happen.

  • 3 Top Marijuana Stocks to Watch in June
    Motley Fool9 days ago

    3 Top Marijuana Stocks to Watch in June

    With the industry possibly cooling off, here are the names to remember.

  • Cronos Stock Is Lagging Other Marijuana Names
    InvestorPlace11 days ago

    Cronos Stock Is Lagging Other Marijuana Names

    After receiving the backing of Altria Group Inc (NYSE:MO), Canada-based cannabis producer Cronos Group (NASDAQ:CRON) looked like it was headed for significant growth, but it has not delivered. As a result, the performance of CRON stock has been disappointingSince the deal, CRON has not made meaningful strides in production, which is the name of the game in cannabis, nor has the company expanded notably overseas. Without even factoring in the valuation of CRON stock, I have serious concerns about the company.CRON just does not have strong enough fundamentals to propel Cronos stock meaningfully higher. The company continues to lag its competitors in production, R&D, and new markets.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks to Buy That Could Be Takeover Targets Capacity WoesCronos' production capacity is comparable to the likes of Organigram and CannTrust Holdings (NYSE:CTST), but the market gives CRON stock a substantially larger valuation.However, it is not clear why that gap is justified, since CRON is a less efficient grower and seller than its two competitors.Cronos, Organigram, and CannTrust Holdings all have similar capacity now and similar estimated capacity next year. Looking at recent results, though, Cronos clearly grows cannabis less efficiently and sells it less effectively. Cronos sold just 1,111 kg of cannabis last year, while Organigram sold 4,248 kg and CannTrust sold over 3,000 kg.Cronos is falling behind tremendously. CRON Doesn't Have an Edge OverseasCRON's international push does not seem to be materially different or more successful than that of its peers. Most of its overseas partnerships are in very competitive areas. Other players have been expanding much more aggressively, and CRON has less ground cultivated overseas than the competition, which will be a hindrance to its growth and to CRON stock.In Australia, for example, Cronos is aiming for annual production capacity of 2,000 kg. But that is peanuts compared to what Solaris Nutraceuticals Pty Ltd is doing. Its greenhouse will produce around 100,000 kg per year of medical cannabis.In Latin America, CRON has a 50/50 joint venture with AGI, Colombia's leading agricultural services provider. However, there has been a big increase in the number of cultivators in the region. Again, just as an example. AGI's 207 acres of available land pales in comparison to competitors like Colombia's Pharmacielo, which has over 15 million square feet of land. That translates roughly to production capacity of over 5,000 kilograms.There's also Khiron, a Colombian grower that has been expanding its own cultivation area. Its total area is estimated to be capable of producing 100,000 kilograms of dry flower for extraction and processing into medical cannabis.You get the idea.Europe is even more crowded. Germany and Poland, where many American-listed Canadian companies have been active in M&A and expanding their footprints, are particularly competitive. The Bottom Line on CRON StockThe cannabis industry is a very attractive space to be in, but there are bound to be some duds. At the moment, Cronos Group stock is shaping up to be a good name to short. One caveat is that Cronos does has a decent cash balance.Overall, investors can always generate profits by reducing exposure to the laggards and doubling down on the leaders. Investors should be reducing their exposure to CRON stock.As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post Cronos Stock Is Lagging Other Marijuana Names appeared first on InvestorPlace.

  • 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3%
    InvestorPlace11 days ago

    7 S&P 500 Dividend Stocks to Buy at Least Yielding 3%

    The other day I read an article about Target (NYSE:TGT) that couldn't stop talking about the discount retailer's healthy 3.2% dividend yield. While anything above 3% certainly can't be ignored, it turns out that 134 S&P 500 stocks currently offer a dividend yield of 3% or higher. So, the 3% yield isn't nearly as unique as many investors believe. For some investors, that means it might be smarter to consider ETFs that focus on dividend yields as part of their stock-selection process. There are two high-dividend ETFs that focus on the S&P 500. InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe first is the Investco S&P 500 High Dividend Low Volatility ETF (NYSEARCA:SPHD). It focuses on the 50 S&P 500 stocks that historically have provided high dividend yields and low volatility. The second is the SPDR Portfolio S&P 500 High Dividend ETF (NYSEARCA:SPYD), which owns 80 high dividend-yielding S&P 500 stocks. Either of these could do the trick. * 10 Stocks to Buy That Could Be Takeover Targets However, this is an article about individual stocks to buy, so I'm going to pick at least three S&P 500 dividend stocks from each of the two ETFs that are currently yielding 3% or more. Ford (F)Source: Jens Mayer via Flickr (Modified)Ford (NYSE:F) is currently yielding 6.1% as of June 5, making it the 11th highest yielding S&P 500 stock. By picking Ford, I'm taking a bit of chance. That's because the truck and car manufacturer stands to be one of the losers should President Trump go ahead with a 5% tariff on goods imported from Mexico. The planned date for implementation is June 10. Mexican officials are negotiating with U.S. officials to avoid what would be an economic disaster on both sides of the border. My InvestorPlace colleague Josh Enomoto recently recommended investors sell Ford stock because it now may have to fight a trade war on two fronts: China and Mexico. I get the sentiment, but Ford's got too much upside potential, including a move into electric vehicles that should see a good chunk of its fleet electrified by the end of 2022. Yielding 6.1% and generating plenty of free cash flow, Ford stock is a great play for dividend investors. Altria (MO)Source: Peyri Herrera via Flickr (Modified)Altria (NYSE:MO) is currently yielding 6.5% as of June 5, making it the 7th highest yielding S&P 500 stock. In recent years, Altria's become known more for its acquisitions outside the cigarette industry, than anything it's done in its core business. On June 3, Altria announced that it was buying 80% of a Swiss smokeless tobacco company, whose smokeless oral pouch On is already sold in the U.S. Paying $372 million for Burger Sohne, it's adding another non-combustible product to the Altria portfolio. In the past year, Altria's paid almost $15 billion to buy a minority stake in e-cigarette maker Juul Labs and a 45% interest in Cronos Group (NASDAQ:CRON), one of Canada's largest cannabis companies. Altria's doing everything it can to ensure that when the cigarette industry dies its ultimate death, these new areas of business will more than compensate for the loss of sales in its legacy business. * 7 Ways to Make Berkshire Hathaway Stock More Attractive Altria's another reliable generator of free cash flow virtually ensuring the long-term payment of its $3.20 a year dividend. Kimco Realty (KIM)Source: Shutterstock The next of our stocks to buy, Kimco Realty (NYSE:KIM), is currently yielding 6.2% as of June 5, making it the 6th highest yielding S&P 500 stock. Year to date, it's up 22.2% including dividends, considerably higher than both the S&P 500 and its real estate investment trust peers. One of the oldest REITs in the U.S., it owns more than 400 shopping centers across the country, providing more than 61 million square feet for potential tenants.For those who might be worried about a REIT involved in the retail industry, Kimco's made sure to get tenants that are changing with the times. Not to mention its shopping centers are located in major metro markets, with 77% of its revenue coming from grocery-anchored malls. In addition, Kimco does a good job diversifying its tenants. It currently has 7,900 leases with 3,700 tenants with the top 12 tenants generating just 22% of its annualized base rent (ABR). The area where investors should focus on is the work Kimco's doing to redevelop some of its malls and shopping centers. In 2021 and beyond, it expects to invest up to $250 million annually to add additional retail and mixed-use redevelopments to existing properties. As the markets begin to lose their luster, stocks like KIM will deliver nice dividends for its shareholders even if the capital appreciation isn't always there. Target (TGT)Source: Mike Mozart via Flickr (Modified)Target is currently yielding 3.0% as of June 5, making it the 136th highest yielding S&P 500 stock. Barely making it on to the list, I picked Target's stock because it appears to be on a bit of a roll in 2019. The discount retailer's latest quarterly results were better-than-expected beating revenue estimates by $140 million and earnings by nine cents a share. However, it was the retailer's same-store sales growth (+4.8%) and online revenue growth (+42%) that really stood out for investors. Not only did online sales grow by 42% in the quarter, they now account for 7.1% of Target's overall sales, 190 basis points higher than a year earlier. To be truly omnichannel, it's got to get to double digits, something I expect it will do by the end of the fiscal year. As a result of its Q1 2019 results, CEO Brian Cornell suggested that Target is "well positioned to deliver strong financial performance in 2019 and beyond."Target expects to earn $5.90 a share in 2019 with same-store sales growth in the low- to mid-single-digits. * 3 All-American ETFs to Consider Buying The investments the company has made in its stores, e-commerce, and supply chain are starting to pay off. As long as the economy remains strong, Target stock could see $100 by the end of the year, making it a prime stock to buy. Public Storage (PSA)Source: Mike Mozart Via FlickrPublic Storage (NYSE:PSA) is currently yielding 3.3% as of June 5, making it the 103rd highest yielding S&P 500 stock. As the tariff wars continue to heat up, investors continue to seek out investments that aren't going to be affected by tariffs on imported Chinese and Mexican goods. One area that stands out as a safe haven is the self-storage industry, an industry that benefits from America's love affair with junk. Public Storage's business has always been an attractive one because it's part self-storage facility and part real estate investment. PSA has 2,444 self-storage facilities in 38 states amounting to 164 million square feet of rentable space. It also owns 35% of European self-storage leader Shurgard, which owns 231 facilities offering 13 million square feet of rentable space. If you look at its balance sheet from the quarter ended March 31, you'll see that Public Storage's real estate is valued on its books at $9.3 billion excluding accumulated depreciation. That's just 1.6% higher than a year earlier. There's a reason for that. The numbers on the balance sheet reflect the cost of the land and its buildings, not the market value they'd generate if they were sold. As the parking lot business, self-storage facilities are a great way to generate income from the real estate until the value becomes such that it's worth more to a developer for apartments, offices, and mixed-use facilities. To be paid 3.3% to wait for the real estate to mature is an outstanding deal. Coty (COTY)Source: Shutterstock Coty (NYSE:COTY) is currently yielding 3.8% as of June 5, making it the 76th highest yielding S&P 500 stock. Up 100.5% year to date including dividends, the maker of beauty brands that include Cover Girl, Max Factor, OPI, and Sally Hansen, also had a strong May, gaining 14% during the month, the second-best performing S&P 500 stock.The company is in the early stages of a turnaround that began by moving Pierre Laubies into the CEO job in November 2018, followed by the hiring of a new CFO in January 2019. The two executives will lead a conference call on July 1 that will cover the critical components of their turnaround plan. As part of the plan, Coty will look to simplify its business to reduce the supply chain problems it's experienced in the past year. Although revenues and earnings are down in 2019, Coty managed to generate free cash flow of $120.5 million in the first nine months of 2019, a considerable turnaround from the negative free cash flow of $129.8 million in the first nine months of 2018. * The 10 Best Stocks for 2019 -- So Far Slowly, the business is improving and a higher share price reflects that. Despite the recent rally, COTY is still a stock to buy. General Mills (GIS)Source: Shutterstock General Mills (NYSE:GIS) is currently yielding 3.8% as of June 5, making it the 76th highest yielding S&P 500 stock. General Mills, like many large packaged foods companies, has suffered in recent years from a move to more healthy alternatives. And while most of the big players have tried to adapt to the new order, they've got a ways to go before they're back on top. At General Mills, it took CEO Jeff Harmening's promotion to the top job in June 2017 to get the ball rolling. But even he'll admit the transformation isn't nearly done. "What I'm most proud of is… the change in culture… We've brought in a lot of people from outside of the organization who have added a lot of value in things like strategic revenue management and global sourcing and ecommerce, and a new chief marketing officer [Ivan Pollard, who came from Coca-Cola North America in July 2017, and is building a global marketing/media planning structure]. And we've blended [them] with our internal talent," Harmening stated recently in an interview. General Mills continues to invest in its e-commerce business, which currently accounts for 3% of sales, and could represent as much as 10% within five years. As for acquisitions, its multi-billion purchase of Blue Buffalo pet foods has been a hit with both e-commerce and the mass retail channels. GIS stock has rebounded nicely in 2019, up 33% year to date, including dividends. As it continues to transform its business, shareholders should see its stock move even higher. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * The 4 FANG Stocks Won't Be Bitten By Regulation Threats * 10 Stocks to Buy That Could Be Takeover Targets * 4 Big Bank Stocks Rebounding Compare Brokers The post 7 S&P 500 Dividend Stocks to Buy at Least Yielding 3% appeared first on InvestorPlace.

  • Benzinga11 days ago

    Analyst Likes Cronos, But Valuation Suggests 'Downside Potential'

    Investors have had an appetite for cannabis stocks since recreational marijuana was legalized in Canada last year. On Thursday, Stifel analyst W. Andrew Carter initiated coverage of Cronos with a Hold rating and C$18 ($13.44 USD) price target. Need more cannabis news?

  • Altria (MO) Stock Sinks As Market Gains: What You Should Know
    Zacks12 days ago

    Altria (MO) Stock Sinks As Market Gains: What You Should Know

    Altria (MO) closed the most recent trading day at $49.69, moving -1.45% from the previous trading session.

  • E-Cig Maker Juul Eyes Its Own Retail Store Chain
    Motley Fool12 days ago

    E-Cig Maker Juul Eyes Its Own Retail Store Chain

    Concerns over teen e-cig usage drives industry leader to assert greater control over access.

  • This Marijuana Stock Holds 'Key To Winning The U.S. Market'
    Investor's Business Daily12 days ago

    This Marijuana Stock Holds 'Key To Winning The U.S. Market'

    Cronos surged on a double upgrade from Bank of America as the Canadian pot producer plots an "aggressive" move into the U.S. CBD market.